(19) | |
| (11) | EP 2 644 194 A3 |
(12) | EUROPEAN PATENT APPLICATION |
(88) | Date of publication A3: | | 01.01.2014 Bulletin 2014/01 |
(43) | Date of publication A2: | | 02.10.2013 Bulletin 2013/40 |
(22) | Date of filing: 10.03.2009 |
| (51) | International Patent Classification (IPC): |
|
(84) | Designated Contracting States: | | AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR | | Designated Extension States: | | AL BA RS |
(30) | Priority: | 18.03.2008 US 37410 P
|
(62) | Application number of the earlier application in accordance with Art. 76 EPC: | | 09721522.2 / 2254571 |
(71) | Applicant: Genentech, Inc. | | South San Francisco, CA 94080 (US) |
| (72) | Inventors: | | - Berry, Leanne
South San Francisco, CA California 94080 (US) - Phillips, Gail, Lewis
San Carlos, CA California 94070 (US) - Sliwkowski, Mark, X.
San Carlos, CA California 94070 (US)
|
(74) | Representative: Kiddle, Simon John | | Mewburn Ellis LLP
33 Gutter Lane London
EC2V 8AS London
EC2V 8AS (GB) |
|
| |
(54) | Combinations of an anti-HER2 antibody-drug conjugate and docetaxel |
(57) Combinations of the antibody-drug conjugate trastuzumab-MCC-DM and docetaxel.